Revenue
2023
2024
2025
Monte Rosa Therapeutics, Inc. (GLUE)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $123.7M | $75.6M | $0 | — | — | — |
| Research & development | $141.5M | $121.6M | $111.3M | $85.1M | $57.2M | $24.0M |
| Operating expenses | $177.9M | $156.7M | $143.3M | $112.4M | $72.9M | $28.0M |
| Operating income | −$54.2M | −$81.1M | −$143.3M | −$112.4M | −$72.9M | −$28.0M |
| EBITDAderived | −$43.4M | −$70.9M | −$135.0M | −$106.1M | — | — |
| Net income | −$38.6M | −$72.7M | −$135.4M | −$108.5M | −$74.0M | −$35.9M |
| Basic EPSper diluted share | — | — | — | — | -$2.96 | -$23.65 |
| Diluted EPSper diluted share | — | — | — | — | -$2.96 | -$23.65 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 · 10b5-1 | Janku FilipChief Medical Officer | SellCommon Stock | 6.0K | $22.95 | $137.7K | 60.0K |
| Jun 29, 2026Form 4 | Manning Anthony M.Director | SellCommon Stock | 10.0K | $23.11 | $231.1K | 0 |
| Jun 24, 2026Form 4 · 10b5-1 | Janku FilipChief Medical Officer | SellCommon Stock | 30.0K | $21.42 | $642.6K | 60.0K |
| Jun 23, 2026Form 4 · 10b5-1 | Janku FilipChief Medical Officer | SellCommon Stock | 11.8K | $20.22 | $239.5K | 60.0K |
| Jun 23, 2026Form 4 · 10b5-1 | Townson SharonChief Scientific Officer | SellCommon Stock | 3.0K | $20.00 | $60.0K | 67.8K |